Looking ahead, Legal & General said it continues to expect full-year core operating earnings per share growth within its three-year target range of 6% to 9%. In the medium-term, the company is ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...